Literature DB >> 20562889

Systems biology and pharmacology.

J M Berg1, M E Rogers, P M Lyster.   

Abstract

Drug action depends not only on the direct consequences of the interaction between the drug and its target but also on other consequences within the complex physiological system that is the human body. The National Institute of General Medical Sciences (NIGMS) has brought together investigators from the emerging field of systems biology with pharmacologists to explore possible avenues for utilizing the concepts of systems biology to explore problems in pharmaceutical action and drug discovery.

Entities:  

Mesh：

Year:  2010        PMID： 20562889     DOI： 10.1038/clpt.2010.69

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  16 in total

1.  Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development.

Authors:  Piet H van der Graaf; Neil Benson
Journal:  Pharm Res       Date:  2011-05-11       Impact factor: 4.200

2.  Clinical trials in the era of personalized oncology.

Authors:  Michael L Maitland; Richard L Schilsky
Journal:  CA Cancer J Clin       Date:  2011-10-27       Impact factor: 508.702

3.  A Perspective on Implementing a Quantitative Systems Pharmacology Platform for Drug Discovery and the Advancement of Personalized Medicine.

Authors:  Andrew M Stern; Mark E Schurdak; Ivet Bahar; Jeremy M Berg; D Lansing Taylor
Journal:  J Biomol Screen       Date:  2016-03-08

4.  Modeling and simulation at the interface of nonclinical and early clinical drug development.

Authors:  S A G Visser; E Manolis; M Danhof; T Kerbusch
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-02-27

5.  NIH Support for the Emergence of Quantitative and Systems Pharmacology.

Authors:  M Rogers; P Lyster; R Okita
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-04-10

6.  Integrated pharmacometrics and systems pharmacology model-based analyses to guide GnRH receptor modulator development for management of endometriosis.

Authors:  M M Riggs; M Bennetts; P H van der Graaf; S W Martin
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-10-17

7.  The grand challenge for integrative and regenerative pharmacology.

Authors:  George J Christ; Alex F Chen
Journal:  Front Pharmacol       Date:  2011-02-14       Impact factor: 5.810

8.  VDA, a method of choosing a better algorithm with fewer validations.

Authors:  Francesco Strino; Fabio Parisi; Yuval Kluger
Journal:  PLoS One       Date:  2011-10-12       Impact factor: 3.240

9.  Bioinformatics challenges for personalized medicine.

Authors:  Guy Haskin Fernald; Emidio Capriotti; Roxana Daneshjou; Konrad J Karczewski; Russ B Altman
Journal:  Bioinformatics       Date:  2011-05-19       Impact factor: 6.937

10.  Targeting human central nervous system protein kinases: An isoform selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models.

Authors:  Saktimayee M Roy; Valerie L Grum-Tokars; James P Schavocky; Faisal Saeed; Agnieszka Staniszewski; Andrew F Teich; Ottavio Arancio; Adam D Bachstetter; Scott J Webster; Linda J Van Eldik; George Minasov; Wayne F Anderson; Jeffrey C Pelletier; D Martin Watterson
Journal:  ACS Chem Neurosci       Date:  2015-02-23       Impact factor: 4.418
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.